시장보고서
상품코드
1957704

단백질 분해 요법 시장 보고서(2026년)

Protein Degradation Therapy Global Market Report 2026

발행일: | 리서치사: 구분자 The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

단백질 분해 요법 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 12억 5,000만 달러에서 2026년에는 13억 5,000만 달러에 이르고, CAGR 8.1%로 성장할 전망입니다. 지난 수년간의 성장에는 분자생물학 연구의 발전, 표적 암 치료의 확대, 단백질 기능 장애에 대한 이해의 심화, 초기 임상시험의 성공, 생명공학 분야의 벤처캐피털 자금 증가 등이 주요 요인으로 꼽힙니다.

단백질 분해 요법 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 18억 3,000만 달러에 이르고, CAGR은 7.8%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 신규 암 치료법에 대한 수요 증가, 정밀 종양학에 대한 투자 확대, 단백질 분해 플랫폼의 확대, 임상시험 활동 활성화, 혁신적 치료법에 대한 규제 당국의 지원 강화 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 표적형 단백질 분해제 개발 증가, 종양학 분야에 대한 관심 증가, PROTAC 기반 치료제에 대한 투자 확대, 임상 파이프라인 후보물질 확대, 제약사와 바이오텍 기업 간 협력 강화 등을 꼽을 수 있습니다.

암에 대한 부담이 증가함에 따라 향후 단백질 분해 요법 시장의 성장을 가속할 것으로 예측됩니다. 암은 체내에서 비정상적인 세포가 통제할 수 없을 정도로 증식, 확산되는 각종 질환을 말합니다. 암 발생률 증가는 고령화, 흡연 등 생활습관, 부적절한 식습관, 운동 부족, 비만율 증가 등의 요인에 기인하며, 이들 모두 각종 암 발생 위험을 증가시킵니다. 단백질 분해 요법은 암의 증식과 생존을 촉진하는 특정 단백질을 표적으로 제거하기 때문에 기존 치료법에 대한 내성을 극복할 수 있는 잠재력을 가지고 있어 암 치료에 있어 매우 중요한 치료법입니다. 예를 들어, 2024년 2월 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)는 2050년까지 신규 암 발병 건수가 3,500만 건을 넘어설 것으로 예측하고 있으며, 이는 2022년 추정치인 2,000만 건에서 77% 증가한 수치입니다. 또한, 인간개발지수(HDI)가 높은 국가에서 절대적으로 가장 큰 증가가 예상되며, 2022년 추정치 대비 2050년에는 480만 건이 새로 발생할 것으로 예측됩니다. 따라서 증가하는 암 부담은 단백질 분해 요법 시장의 확대를 촉진하고 있습니다.

단백질 분해 치료제 시장의 주요 기업들은 혁신적인 치료법 개발, 상호보완적인 전문 지식 활용, 자원 공유, 질병 원인 단백질을 표적으로 하는 신약 후보물질 발굴 및 개발 가속화를 위해 전략적 제휴를 맺고 있습니다. 이러한 제휴를 통해 양사는 서로의 강점과 자원을 활용하여 상호 이익을 얻고 공동의 성공을 달성할 수 있습니다. 예를 들어, 2024년 2월 미국 생명공학 기업 아르비나스(Arvinas)는 최초의 경구용 PROTAC 분해제(ARV-102)를 발표했습니다. 이 약은 혈액뇌장벽을 통과하여 신경퇴행성 질환 치료를 목적으로 LRRK2를 표적으로 합니다. ARV-102 분자는 경구 생체 이용률, 뇌 투과성, LRRK2에 대한 높은 특이성을 가지고 있습니다. 이 혁신적인 기술은 기존에 치료하기 어려웠던 표적을 타겟으로 하여 회사의 파이프라인을 강화하는 한편, 분자 구조가 크기 때문에 장기적인 안전성, 제조의 복잡성, 약동학 최적화에 대한 과제가 남아있습니다.

자주 묻는 질문

  • 단백질 분해 요법 시장 규모는 어떻게 변화하고 있나요?
  • 단백질 분해 요법 시장의 성장 요인은 무엇인가요?
  • 단백질 분해 요법이 암 치료에 중요한 이유는 무엇인가요?
  • 단백질 분해 치료제 시장의 주요 기업들은 어떤 전략을 취하고 있나요?
  • WHO의 암 발생 예측은 어떻게 되나요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

LSH 26.04.02

Protein degradation therapy is a therapeutic approach that focuses on the selective degradation of specific proteins within cells. This method involves using small molecules, peptides, or other agents to promote the destruction of proteins that are dysfunctional or contribute to disease. The aim is to reduce or eliminate harmful proteins associated with various conditions, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Key therapies in protein degradation include bavdegalutamide (ARV-110), vepdegestrant (ARV-471), and others. Bavdegalutamide, also known as ARV-110, is a novel therapy developed to target and degrade androgen receptors in prostate cancer cells. This therapy is used in the treatment of oncology, neurodegenerative diseases, infectious diseases, and other conditions by various end-users, including pharmaceutical companies, biotechnology companies, and academic and research institutes.

Tariffs are influencing the protein degradation therapy market by increasing costs of imported research reagents, laboratory equipment, specialized chemical compounds, and bioprocessing tools used in drug discovery and clinical development. Biotechnology hubs in North America and Europe are most affected due to reliance on imported research materials, while Asia-Pacific faces cost pressure on compound synthesis and testing. These tariffs are raising R&D expenditures and extending development timelines. However, they are also encouraging localized research infrastructure, domestic reagent production, and regional partnerships in advanced therapeutic development.

The protein degradation therapy market research report is one of a series of new reports from The Business Research Company that provides protein degradation therapy market statistics, including protein degradation therapy industry global market size, regional shares, competitors with a protein degradation therapy market share, detailed protein degradation therapy market segments, market trends and opportunities, and any further data you may need to thrive in the protein degradation therapy industry. This protein degradation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The protein degradation therapy market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.35 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to advancements in molecular biology research, expansion of targeted cancer therapies, increased understanding of protein dysfunction in diseases, early-stage clinical successes, growing venture capital funding in biotech.

The protein degradation therapy market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing demand for novel cancer therapies, rising investments in precision oncology, expansion of protein degradation platforms, growing clinical trial activity, increasing regulatory support for innovative therapeutics. Major trends in the forecast period include increasing development of targeted protein degraders, rising focus on oncology applications, growing investment in protac-based therapies, expansion of clinical pipeline candidates, enhanced collaboration between pharma and biotech firms.

The increasing burden of cancer is expected to drive the growth of the protein degradation therapy market in the future. Cancer encompasses a variety of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rising cancer rates are largely due to factors such as an aging population, lifestyle choices like smoking, poor diet, lack of physical activity, and increasing obesity rates, all of which have heightened the risk of different cancers. Protein degradation therapy is vital for treating cancer because it targets and eliminates specific proteins that promote cancer growth and survival, potentially overcoming resistance to conventional treatments. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, predicted that over 35 million new cancer cases are expected by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Furthermore, high human development index (HDI) countries are forecasted to experience the largest rise in absolute numbers, with an additional 4.8 million new cases in 2050 compared to 2022 estimates. Therefore, the growing cancer burden is fueling the expansion of the protein degradation therapy market.

Leading companies in the protein degradation therapy market are forming strategic partnerships to develop innovative therapies, leverage complementary expertise, share resources, and accelerate the discovery and development of new drug candidates targeting disease-causing proteins. These partnerships enable companies to use each other's strengths and resources to gain mutual benefits and achieve shared success. For example, in February 2024, Arvinas, a U.S.-based biotechnology company, launched its first oral PROTAC degrader (ARV-102), designed to cross the blood-brain barrier and target LRRK2 for neurodegenerative disease applications. The ARV-102 molecule offers oral bioavailability, brain penetration, and high specificity for LRRK2. This innovation strengthens the company's pipeline by targeting previously undruggable targets, although challenges remain around long-term safety, manufacturing complexity, and optimizing pharmacokinetics due to the larger molecular structure.

In June 2024, Genexine, a South Korea-based biopharmaceutical company, merged with EPD Biotherapeutics for an undisclosed amount. This merger enabled Genexine to acquire key talent and cutting-edge technology, positioning it to lead the global market. Additionally, the integration of EPD Bio's bioPROTAC technology with Genexine's clinical and CMC development capabilities is expected to accelerate the development of groundbreaking new drugs. EPD Biotherapeutics is a South Korea-based developer of the protein degradation platform known as EPDeg.

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc

North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the protein degradation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The protein degradation therapy market consists of revenues earned by entities by providing services such as drug discovery and development, target validation, preclinical and clinical testing and targeted protein degradation screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The protein degradation therapy market also includes sales of degraders, E3 ligase ligands, degron tags, biochemical assay kits and cellular assay kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Protein Degradation Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses protein degradation therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for protein degradation therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The protein degradation therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Bavdegalutamide (ARV - 110); Vepdegestrant (ARV - 471)
  • 2) By Application: Oncology; Neurodegenerative Diseases; Infectious Diseases; Other Applications
  • 3) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes
  • Subsegments:
  • 1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders; Prostate Cancer Therapy
  • 2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders; Breast Cancer Therapy
  • Companies Mentioned: Relay Therapeutics; Arvinas Holding Company LLC; Kymera Therapeutics; Nurix Therapeutics; Vividion Therapeutics; Mission Therapeutics Ltd.; C4 Therapeutics Inc.; Cullgen Inc.; Frontier Medicines; Foghorn Therapeutics; Aileron Therapeutics; Ribometrix Inc.; Nimbus Therapeutics; Jnana Therapeutics; KSQ Therapeutics; Stoke Therapeutics; Flare Therapeutics; Accent Therapeutics; Monte Rosa Therapeutics; Lycia Therapeutics; Dialectic Therapeutics; Amphista Therapeutics; Biotheryx Inc.; Cedilla Therapeutics; Dewpoint Therapeutics Inc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Protein Degradation Therapy Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Protein Degradation Therapy Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Protein Degradation Therapy Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Protein Degradation Therapy Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Increasing Development Of Targeted Protein Degraders
    • 4.2.2 Rising Focus On Oncology Applications
    • 4.2.3 Growing Investment In Protac-Based Therapies
    • 4.2.4 Expansion Of Clinical Pipeline Candidates
    • 4.2.5 Enhanced Collaboration Between Pharma And Biotech Firms

5. Protein Degradation Therapy Market Analysis Of End Use Industries

  • 5.1 Pharmaceutical Companies
  • 5.2 Biotechnology Companies
  • 5.3 Contract Research Organizations
  • 5.4 Academic And Research Institutes
  • 5.5 Clinical Research Centers

6. Protein Degradation Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Protein Degradation Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Protein Degradation Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Protein Degradation Therapy Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Protein Degradation Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Protein Degradation Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Protein Degradation Therapy Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Protein Degradation Therapy Market Segmentation

  • 9.1. Global Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Bavdegalutamide (ARV - 110), Vepdegestrant (ARV - 471)
  • 9.2. Global Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology, Neurodegenerative Diseases, Infectious Diseases, Other Applications
  • 9.3. Global Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes
  • 9.4. Global Protein Degradation Therapy Market, Sub-Segmentation Of Bavdegalutamide (ARV-110), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Androgen Receptor Degraders, Prostate Cancer Therapy
  • 9.5. Global Protein Degradation Therapy Market, Sub-Segmentation Of Vepdegestrant (ARV-471), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Estrogen Receptor Degraders, Breast Cancer Therapy

10. Protein Degradation Therapy Market Regional And Country Analysis

  • 10.1. Global Protein Degradation Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Protein Degradation Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Protein Degradation Therapy Market

  • 11.1. Asia-Pacific Protein Degradation Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Protein Degradation Therapy Market

  • 12.1. China Protein Degradation Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Protein Degradation Therapy Market

  • 13.1. India Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Protein Degradation Therapy Market

  • 14.1. Japan Protein Degradation Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Protein Degradation Therapy Market

  • 15.1. Australia Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Protein Degradation Therapy Market

  • 16.1. Indonesia Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Protein Degradation Therapy Market

  • 17.1. South Korea Protein Degradation Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Protein Degradation Therapy Market

  • 18.1. Taiwan Protein Degradation Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Protein Degradation Therapy Market

  • 19.1. South East Asia Protein Degradation Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Protein Degradation Therapy Market

  • 20.1. Western Europe Protein Degradation Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Protein Degradation Therapy Market

  • 21.1. UK Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Protein Degradation Therapy Market

  • 22.1. Germany Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Protein Degradation Therapy Market

  • 23.1. France Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Protein Degradation Therapy Market

  • 24.1. Italy Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Protein Degradation Therapy Market

  • 25.1. Spain Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Protein Degradation Therapy Market

  • 26.1. Eastern Europe Protein Degradation Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Protein Degradation Therapy Market

  • 27.1. Russia Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Protein Degradation Therapy Market

  • 28.1. North America Protein Degradation Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Protein Degradation Therapy Market

  • 29.1. USA Protein Degradation Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Protein Degradation Therapy Market

  • 30.1. Canada Protein Degradation Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Protein Degradation Therapy Market

  • 31.1. South America Protein Degradation Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Protein Degradation Therapy Market

  • 32.1. Brazil Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Protein Degradation Therapy Market

  • 33.1. Middle East Protein Degradation Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Protein Degradation Therapy Market

  • 34.1. Africa Protein Degradation Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Protein Degradation Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Protein Degradation Therapy Market Regulatory and Investment Landscape

36. Protein Degradation Therapy Market Competitive Landscape And Company Profiles

  • 36.1. Protein Degradation Therapy Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Protein Degradation Therapy Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Protein Degradation Therapy Market Company Profiles
    • 36.3.1. Relay Therapeutics Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Arvinas Holding Company LLC Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Kymera Therapeutics Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Nurix Therapeutics Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Vividion Therapeutics Overview, Products and Services, Strategy and Financial Analysis

37. Protein Degradation Therapy Market Other Major And Innovative Companies

  • Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics

38. Global Protein Degradation Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Protein Degradation Therapy Market

40. Protein Degradation Therapy Market High Potential Countries, Segments and Strategies

  • 40.1 Protein Degradation Therapy Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Protein Degradation Therapy Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Protein Degradation Therapy Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제